Advanced Endometrial Cancer
SNSESensei BiotherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Piktor (PI3K/mTOR Inhibitor) in Advanced Endometrial Cancer. The expected timing is based on the latest available company guidance and may change.
05/15/26:- FTH-PIK-201 remains on track. Topline Ph2 data expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.